Patents by Inventor James E. Crowe, Jr.

James E. Crowe, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200040066
    Abstract: The present disclosure is directed to antibodies binding to Marburg virus (MARV) glycoprotein (GP) and methods of use therefore.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 6, 2020
    Inventors: James E. CROWE, Jr., Andrew I. FLYAK, Alexander BUKREYEV, Philipp ILINYKH
  • Publication number: 20200010536
    Abstract: The present disclosure is directed to antibodies binding to prefusion and postfusion forms of both human S. aureus and human metapneumovirus F proteins, including neutralizing antibodies, and methods for use thereof.
    Type: Application
    Filed: March 6, 2018
    Publication date: January 9, 2020
    Applicant: Vanderbilt University
    Inventors: James E. CROWE, Jr., Gopal SAPPARAPU, Isaac THOMSEN, Buddy CREECH
  • Publication number: 20190367586
    Abstract: The present disclosure is directed to antibodies binding to human respiratory syncytial virus F protein, including both neutralizing and non-neutralizing antibodies, and methods for use thereof.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 5, 2019
    Applicant: Vanderbilt University
    Inventors: James E. Crowe, JR., Jarrod Mousa
  • Publication number: 20190276520
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Zika virus and methods for use thereof.
    Type: Application
    Filed: November 1, 2017
    Publication date: September 12, 2019
    Applicant: Vanderbilt University
    Inventor: James E. CROWE, JR.
  • Publication number: 20190255168
    Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein domain I and domain II hinge region from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
    Type: Application
    Filed: September 28, 2018
    Publication date: August 22, 2019
    Inventors: Aravinda M. de Silva, A. Ruklanthi de Alwis, Wahala M.P.B. Wahala, Ralph S. Baric, William B. Messer, James E. Crowe, JR., Scott A. Smith
  • Publication number: 20190240316
    Abstract: The present disclosure is directed to antibodies binding to human respiratory syncytial virus F protein, including both neutralizing and non-neutralizing antibodies, and methods for use thereof.
    Type: Application
    Filed: October 16, 2017
    Publication date: August 8, 2019
    Applicant: Vanderbilt University
    Inventors: James E. Crowe, Jr., Jarrod Mousa
  • Patent number: 10117924
    Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein domain I and domain II hinge region from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: November 6, 2018
    Assignees: The University of North Carolina at Chapel Hill, Vanderbilt University
    Inventors: Aravinda M. de Silva, A. Ruklanthi de Alwis, Wahala M. P. B. Wahala, Ralph S. Baric, William B. Messer, James E. Crowe, Jr., Scott A. Smith
  • Publication number: 20180180614
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the iminunodetection methods described above.
    Type: Application
    Filed: March 25, 2016
    Publication date: June 28, 2018
    Inventors: James E. CROWE, JR., Andrew I. FLYAK, Alexander BUKREYEV, Philipp ILINYKH
  • Publication number: 20180125964
    Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein domain I and domain II hinge region from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
    Type: Application
    Filed: October 13, 2017
    Publication date: May 10, 2018
    Inventors: Aravinda M. de Silva, A. Ruklanthi de Alwis, Wahala M.P.B. Wahala, Ralph S. Baric, William B. Messer, James E. Crowe, JR., Scott A. Smith
  • Publication number: 20180079802
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.
    Type: Application
    Filed: April 14, 2016
    Publication date: March 22, 2018
    Inventors: James E. CROWE, Jr., Scott A. SMITH, Terence DERMODY, Laurie SILVA
  • Patent number: 9821050
    Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein domain I and domain II hinge region from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 21, 2017
    Assignees: The University of North Carolina at Chapel Hill, Vanderbilt University
    Inventors: Aravinda M. De Silva, A. Ruklanthi De Alwis, Wahala M. P. B. Wahala, Ralph S. Baric, William B. Messer, James E. Crowe, Jr., Scott A. Smith
  • Publication number: 20150315174
    Abstract: In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds or compositions of the invention and a pharmaceutically acceptable carrier. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: March 3, 2015
    Publication date: November 5, 2015
    Inventors: Eva M. Harth, James E. Crowe, JR., Kui Huang, Sharon K. Hamilton, Heidi E. Hamm, Bryan Voss
  • Patent number: 8969622
    Abstract: In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds or compositions of the invention and a pharmaceutically acceptable carrier. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: March 3, 2015
    Assignee: Vanderbilt University
    Inventors: Eva M. Harth, James E. Crowe, Jr., Kui Huang, Sharon K. Hamilton, Heidi E. Hamm, Bryan Voss
  • Patent number: 8221759
    Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: July 17, 2012
    Assignee: Intracel Resources LLC
    Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, Jr., Brian R. Murphy
  • Publication number: 20120100142
    Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of H1N1 influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies.
    Type: Application
    Filed: April 30, 2010
    Publication date: April 26, 2012
    Inventors: James E. Crowe, JR., Jens C. Krause, Christopher F. Basler
  • Publication number: 20120087909
    Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: September 30, 2011
    Publication date: April 12, 2012
    Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, JR., Brian R. Murphy
  • Patent number: 7867497
    Abstract: The present invention is directed to particular human monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of respiratory syncytial virus infections. In particular, these antibodies may neutralize RSV. Also disclosed are improved methods for producing monoclonal antibodies.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: January 11, 2011
    Assignee: Vanderbilt University
    Inventor: James E. Crowe, Jr.
  • Publication number: 20100040650
    Abstract: The present invention is directed to alphavirus virus-like particles produced by synthesizing in cell, including in vivo, structural proteins in the absence of other alphavirus proteins. In particular, these virus-like particules vaccines induce cellular and humoral immune responses that can block or inhibit alphavirus infections. Also disclosed are methods of vaccinating subjects with virus-like particles and vectors encoding the same.
    Type: Application
    Filed: June 1, 2009
    Publication date: February 18, 2010
    Inventors: James E. Crowe, JR., Hoyin Mok
  • Publication number: 20090162395
    Abstract: The present invention is directed to alphavirus vectored vaccine contructs encoding paramyxovirus proteins that find use in the prevention of respiratory syncytial virus or human metapneumovirus infections. In particular, these vaccines induce cellular and humoral immune responses that inhibit RSV. Also disclosed are improved methods for producing alphavirus vectored paramyxovirus vaccines.
    Type: Application
    Filed: September 25, 2008
    Publication date: June 25, 2009
    Inventors: James E. Crowe, JR., Hoyin Mok, Robert E. Johnston, John V. Williams, Nancy L. Davis
  • Publication number: 20090110684
    Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: April 24, 2008
    Publication date: April 30, 2009
    Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, JR., Brian R. Murphy